Daclatasvir is a new medication approved by US FDA to treat Hepatitis C. It’s a research product of Bristol Myer Squibb and marketed in the brand name Daklinza.Beacon Pharmaceuticals Ltd is the 1st global company to introduce copy of Daklinza in the brand name Daclavir. Considering the affordibility of global patient we have offered the product at a very affordable price, which costs 160 time lesser price than originator brand. Full treatment cost by our brand is only US$ 384,where as cost by originator is $ 6300-said Mr. Karim , Managing Director of Beacon.
Hepatitis C is a viral disease that causes inflammation of the liver that lead to diminished liver function or liver failure. Globally, about 170-185 million population are chronically infected with Hepatitis C virus. In Bangladesh, Hepatitis emerges as a major health problem with nearly 2 million people is infected by Hepatitis virus. The US FDA approved the use of Daclatasvir together with another novel Hep C drugs, sofosbuvir for the treatment Hepatitis.